NCT05063851Active, not recruitingPhase 2
The Use of Memantine for Prevention of Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. AD is caused by the dysfunction, loss of synapses, and eventual neuronal death, which may occur up to 25 years before clinical symptoms appear. This study, based off of pre-clinical data, seeks to assess whether it is feasible to use memantine hydrochloride for the prevention of Alzheimer's Disease.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 23 Jul 2021
- Start date
- 11 Oct 2021
- Primary completion date
- Dec 2026
- Lead sponsor
- University of Virginia
- Diseases
- Alzheimer disease
- NCT number
- NCT05063851
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 32
- From 11 Oct 2021 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications for MRI (e.g., prostheses, implants, claustrophobia, pacemaker) or PET imaging.
- Use of an investigational medical device within 3 months before the planned start of study.
- Current participation in an interventional study with an investigational drug component.
- Major surgery (e.g., requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has major surgery planned during the time the subject is expected to participate in the study.
- Requires treatment with an AChE inhibitor or any of the following: acetazolamide, methazolamide, amantadine, ketamine, dextromethorphan.
Other illness
- A current clinical condition or requires a medication that raises the pH of their urine.
- Severe renal or hepatic impairment.
- Neurodegenerative disorder known to cause neurocognitive decline
- Relevant history of or current neurological disease other than preclinical AD, which may make interpretation of possible new neurological signs or symptoms difficult.
- Clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease
- Ongoing cancer treatment
- Clinically significant and active psychiatric disorder
Other
- Any other abnormality that could cause a possible cognitive deficit (including, but not limited to, vascular encephalopathy or large strokes).
Who the study is looking for
- Be between the age of 50 and 65 years at time of informed consent.
- Have a positive family history for dementia (minimum of 1 first degree relative).
- Previously known or documented heterozygote or homozygote ApoE ε4 allele.
- Be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests.
- Be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline.
- Have Montreal Cognitive Assessment (MOCA) score of 27 or above.
- Have a creatinine clearance (CrCl), estimated using the Cockcroft-Gault formula, greater or equal to 30 mL/minute.
Age in the registry: 50 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Virginia Coordinator of this site? Confirm its status | Charlottesville | United States | Unknown status |
Related publications
- The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol.Contemp Clin Trials Commun · 2026 · PMID 42179865
This page is information, not medical advice. Discuss any trial with your doctor.